Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-5 of 5
Keywords: Sunitinib
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Eric Raymond, Matthew H. Kulke, Shukui Qin, Xianjun Yu, Michael Schenker, Antonio Cubillo, Wenhui Lou, Jiri Tomasek, Espen Thiis-Evensen, Jian-Ming Xu, Adina E. Croitoru, Mustafa Khasraw, Eva Sedlackova, Ivan Borbath, Paul Ruff, Paul E. Oberstein, Tetsuhide Ito, Liqun Jia, Pascal Hammel, Lin Shen, Shailesh V. Shrikhande, Yali Shen, Jozef Sufliarsky, Gazala N. Khan, Chigusa Morizane, Salvatore Galdy, Reza Khosravan, Kathrine C. Fernandez, Brad Rosbrook, Nicola Fazio
Journal:
Neuroendocrinology
Neuroendocrinology (2018) 107 (3): 237–245.
Published Online: 10 July 2018
...; Shailesh V. Shrikhande; Yali Shen; Jozef Sufliarsky; Gazala N. Khan; Chigusa Morizane; Salvatore Galdy; Reza Khosravan; Kathrine C. Fernandez; Brad Rosbrook; Nicola Fazio Background: In a phase III study, sunitinib led to a significant increase in progression-free survival (PFS) versus placebo in patients...
Journal Articles
Anna Pellat, Chantal Dreyer, Camille Couffignal, Thomas Walter, Catherine Lombard-Bohas, Patricia Niccoli, Jean François Seitz, Olivia Hentic, Thierry André, Romain Coriat, Sandrine Faivre, Magaly Zappa, Philippe Ruszniewski, Nicolas Pote, Anne Couvelard, Eric Raymond
Journal:
Neuroendocrinology
Neuroendocrinology (2018) 107 (1): 24–31.
Published Online: 08 March 2018
... is extensively developed in well-differentiated pancreatic neuroendocrine tumours (PanNET) where sunitinib was shown to prolong progression-free survival, leading to nationwide approval. However, clinical experience in patients with grade 3 gastroenteropancreatic neuroendocrine neoplasms (GEPNEN-G3) remains...
Journal Articles
Journal:
Neuroendocrinology
Neuroendocrinology (2017) 105 (4): 394–402.
Published Online: 01 April 2017
...Anna Angelousi; Kimberly Kamp; Maria Kaltsatou; Dermot O'Toole; Gregory Kaltsas; Wouter de Herder Objective: Alternating treatment with sunitinib and everolimus has been shown to be efficacious in renal cell carcinoma. However, no data currently exist for the role of alternate sequence...
Journal Articles
Marianne Pavel, Juan W. Valle, Barbro Eriksson, Anja Rinke, Martyn Caplin, Jie Chen, Frederico Costa, Jenny Falkerby, Nicola Fazio, Vera Gorbounova, Wouter de Herder, Matthew Kulke, Catherine Lombard-Bohas, Juan O'Connor, Halfdan Sorbye, Rocio Garcia-Carbonero, all other Antibes Consensus Conference participants
Journal:
Neuroendocrinology
Neuroendocrinology (2017) 105 (3): 266–280.
Published Online: 29 March 2017
... with biotherapy. More recently, novel targeted drugs, such as the mammalian target of rapamycin inhibitor everolimus and the multiple tyrosine kinase inhibitor sunitinib, have been introduced in the management of NETs. Although targeted drugs are generally well tolerated, with most adverse events being of mild...
Journal Articles
Adrian Lee, David L. Chan, Matthew H. Wong, Bob T. Li, Sumit Lumba, Stephen J. Clarke, Jaswinder Samra, Nick Pavlakis
Journal:
Neuroendocrinology
Neuroendocrinology (2017) 104 (3): 209–222.
Published Online: 16 April 2016
... with octreotide LAR against octreotide LAR alone in mixed NET, Yao et al. [ 10 ] compared everolimus with placebo in patients with pancreatic NET (pNET), and Yao [ 11 ] compared everolimus with placebo in nonpancreatic NET patients (including primary pulmonary NET). Raymond et al. [ 12 ] compared sunitinib...